Effects of doxazosin and atenolol on circulating endothelin-1 and von Willebrand factor in hypertensive middle-aged men

Journal of Cardiovascular Pharmacology

Volumn 34, Issue 4, 1999, Pages 584-588

  Seljeflot, Ingebjørg ^a   Arnesen, Harald ^a   Andersen, Per ^a   Aspelin, Trude ^a   Kierulf, Peter ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Endothelial function; Endothelin 1; Hypertension; Von Willebrand factor; Blockade; Blockade

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; ENDOTHELIN 1; VON WILLEBRAND FACTOR;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

EID: 0032833692     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199910000-00016     Document Type: Article

References (28)

1. Alexander RW. Hypertension and the pathogenesis of atherosclerosis: oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension 1995;25:155-61.
2. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-9.
3. Panza JA, Quyyumi AA, Brush JE, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990;323:22-7.
4. Todd ME. Hypertensive structural changes in blood vessels: do endothelial cells hold the key? Can J Physiol Pharmacol 1992;70: 536-51.
5. Blann A, Seigneur M. Endothelial cell markers in peripheral disease and vascular surgery. Crit Ischaemia 1996;6:87-95.
6. Badimon L, Badimon JJ, Chesebro JH, Fuster V. von Willebrand factor and cardiovascular disease. Thromb Haemost 1993;70: 111-8.
7. Blann AD, Naqvi T, Waite M, McCollum CN. von Willebrand factor and endothelial damage in hypertension. J Hum Hypertens 1993;7:107-11.
8. Yanagiasawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-5.
9. Lüscher TF, Seo B, Bühler FR. Potential role of endothelin in hypertension. Hypertension 1993;21:752-7.
10. Kohno M, Yasumari K, Murakawa KI, et al. Plasma immunoreactive endothelin in essential hypertension. Am J Med 1990;88: 614-8.
11. Schiffrin EL, Thibault G. Plasma endothelin in human essential hypertension. Am J Hypertens 1991;4:303-8.
12. Clozel M, Breu V, Burri K, et al. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature 1993;365:759-61.
13. Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med 1998;338:784-90.
14. Wagner OF, Christ G, Woijta J, et al. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 1992;267:16066-8.
15. Haynes WG, Webb DJ. The endothelin family of peptides: local hormones with diverse roles in health and disease? Clin Sci 1993; 84:485-500.
16. Schiffrin EL. Endothelin: potential role in hypertension and vascular hypertrophy. Hypertension 1995;25:6:1135-43.
17. Sleight P. The sympathetic nervous system in hypertension: differing effects of drug treatment. Eur Heart J 1998;19(suppl F): F39-44.
18. Andersen P, Seljeflot I, Herzog A, Arnesen A, Hjermann I, Holme I. Effects of doxazosin and atenolol on atherothrombogenic risk profile in hypertensive middle-aged men. J Cardiovasc Pharmacol 1998;31:677-83.
19. Treasure CB, Klein JL, Weinstraub WS, et al. Beneficial effect of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-7.
20. Blann AD, Jackson P, Bath PMW, Watts GF. Associations between nutrient intake and serum von Willebrand factor in patients with coronary artery disease. J Intern Med 1995;237:557-61.
21. Blann AD, Waite MA. von Willebrand factor and soluble E-selectin in hypertension: influence of treatment and value in predicting the progression of atherosclerosis. Coron Artery Dis 1996; 7:143-7.
22. Schiffrin EL, Deng LY, Larochelle P. Effects of a β-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. Hypertension 1994;23:83-91.
23. Krum H, Anguo G, Wilshire-Clement M, et al. Changes in plasma endothelin-1 levels reflect clinical response to β-blockade in chronic heart failure. Am Heart J 1996;131:337-41.
24. Emori T, Hirata Y, Ohta K, et al. Cellular mechanisms of endothelin-1 release by angiotensin and vasopressin. Hypertension 1991;18:165-70.
25. Dohi Y, Hahn AWA, Boulanger CM, Bühler FR, Lüscher TF. Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries. Hypertension 1992;19:131-7.
26. Rajagopalan S, Kurz S, Munstel T, et al. Angiotensin II mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vascular tone. J Clin Invest 1996;97:1916-23.
27. Jessup W. Oxidized lipoproteins and nitric oxide. Curr Opin Lipidol 1996;7:274-80.
28. Boulanger C, Lüscher TF. Release of endothelin from the porcine aorta: inhibition by endothelium-derived nitric oxide. J Clin Invest 1990;85:587-90.